AbbVie

ABBV

North Chicago, United States· Est. 2013

abbviecontractmfg.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ABBV · Stock Price

USD 202.71+18.11 (+9.81%)

Market Cap: $355.2B

Historical price data

Overview

AbbVie's mission is to discover and deliver transformative medicines that solve serious health issues. Its landmark achievement was building the world's top-selling drug, Humira, into a franchise while successfully navigating its patent expiry through a robust pipeline and strategic acquisitions like Allergan. The company's strategy hinges on sustained leadership in immunology, accelerated growth in oncology and neuroscience, and financial discipline to fuel high R&D investment and shareholder returns.

ImmunologyOncologyNeuroscienceEye CareVirology

Technology Platform

A diversified multi-modal platform integrating small molecules, advanced biologics & monoclonal antibodies (including bispecifics and ADCs), and next-generation approaches like cell and gene therapies to target serious diseases.

Pipeline

200

200 drugs in pipeline142 in Phase 3

Drug	Indication	Stage
Risankizumab + Risankizumab + Ustekinumab + Ustekinumab	Crohn's Disease (CD)	Phase 3
Atogepant + Placebo for Atogepant	Menstrual Migraine (MM)	Phase 3
ABT-493/ABT-530	Chronic Hepatitis C Virus (HCV) Infection	Phase 3
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a...	Relapsing-Remitting Multiple Sclerosis	Phase 3
Upadacitinib + Dupilumab + Placebo to dupilumab + Placebo to...	Atopic Dermatitis	Phase 3

Funding History

IPOUndisclosedUndisclosedJan 2, 2013

FDA Approved Drugs

EMRELISBLAMay 14, 2025

EMBLAVEONDAFeb 7, 2025

VYALEVNDAOct 16, 2024

Opportunities

Significant growth runway for Skyrizi and Rinvoq in immunology through new indications and geographic expansion.

The ADC and bispecific platforms in oncology offer potential for breakthrough therapies in solid and hematologic tumors.

An aging global population drives durable demand in neuroscience and eye care franchises.

Risk Factors

Intensifying competition and pricing pressure across all core therapeutic areas threaten market share and margins.

Future patent expirations for key assets like Venclexta and Imbruvica present a recurring revenue cliff.

Clinical or regulatory setbacks in the late-stage pipeline could impair long-term growth projections.

Competitive Landscape

AbbVie faces intense competition from global pharma leaders: in Immunology from Johnson & Johnson and Amgen; in Oncology from Merck, Roche, and Bristol Myers Squibb; in Neuroscience from Biogen and Otsuka. Its competitive edge relies on best-in-class efficacy profiles, a multi-modal pipeline, and a formidable global commercial organization.